Ardolino Luke, Lau Brandon, Wilson Isabella, Chen Julia, Borella Linda, Stone Emily, Lim Elgene
Department of Medical Oncology, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
St. Vincent's Clinical School, University of New South Wales, Darlinghurst, NSW, Australia.
Front Oncol. 2021 Jun 23;11:701424. doi: 10.3389/fonc.2021.701424. eCollection 2021.
Taxane-based chemotherapy regimens are in widespread use as standard of care treatment for patients with early breast cancer, though rarely its use can be complicated by taxane-induced pneumonitis (TIP). While breast cancer is the most diagnosed cancer in women worldwide, TIP remains under-described in this setting. Key questions relate to its incidence, diagnosis and management, potential predictive biomarkers, and the balance between this life-threatening toxicity and curatively intended treatment. At a single Australian institution, 6 cases of TIP are identified among 132 patients treated with a paclitaxel-containing regimen for early breast cancer (4.55%, 95% confidence interval 1.69-9.63%). This review first outlines the presentation, management, and outcomes for these cases, then answers these questions and proposes an approach to suspected TIP in patients with breast cancer.
基于紫杉烷的化疗方案作为早期乳腺癌患者的标准治疗方法被广泛应用，尽管紫杉烷诱导的肺炎（TIP）很少会使其使用变得复杂。虽然乳腺癌是全球女性中诊断最多的癌症，但在这种情况下，TIP的描述仍然不足。关键问题涉及其发病率、诊断和管理、潜在的预测生物标志物，以及这种危及生命的毒性与根治性治疗之间的平衡。在澳大利亚的一家机构中，在132例接受含紫杉醇方案治疗早期乳腺癌的患者中，发现了6例TIP（4.55%，95%置信区间1.69-9.63%）。本综述首先概述了这些病例的表现、管理和结果，然后回答这些问题，并提出一种针对疑似乳腺癌患者TIP的处理方法。
